Compare Moderna, Inc. (MRNA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Uranium Energy Corp — how do they compare? Moderna, Inc. trades at $136.8 (market cap $54.14B), while Uranium Energy Corp trades at $11.63 (market cap $5.74B). The key difference: Moderna, Inc. is far larger — about 9.4× Uranium Energy Corp's market cap, and Moderna, Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| MRNA | UEC | |
|---|---|---|
Market Cap | $54.14B | $5.74B |
Sector | Health | Energy |
52-Week High | $174.38 | $20.14 |
52-Week Low | $22.36 | $9.04 |
Enterprise Value | $50.29B | $5.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
UEC is trading at $11.89, up 3.03% today, with a bullish technical signal despite negative profitability metrics. The company reported a net loss of $87.66 million in 2025 with revenue of $66.84 million, though it beat Q4 2025 EPS expectations. Analyst sentiment remains strongly positive with 87.5% buy ratings, supported by institutional interest including BlackRock's recent $432.68 million investment.
The outlook for UEC is mixed, with strong analyst support and nuclear energy tailwinds offset by persistent losses and negative margins. Key risks include execution challenges and uranium price volatility, while opportunities lie in the growing nuclear power sector and institutional backing. The stock trades near recent support levels with technical indicators suggesting potential near-term strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
